Medpace Holdings, Inc. (MEDP) PEG Ratio: 1.82
Is Medpace Holdings, Inc.’s PEG ratio high or low?
Medpace Holdings, Inc.'s PEG ratio of 1.82 is 55% above its 5-year average of 1.18, near the high end of its 5-year range (0.57–1.82).
49.79% above its 12-month average of 1.22.
MEDP PEG Ratio Chart
MEDP Average PEG Ratio Chart
MEDP Current vs Average PEG Ratio Chart
MEDP PEG Ratio Metrics
PEG RATIO
1.82
PEG RATIO AVG TTM
1.22
PEG RATIO AVG 3Y
1.14
PEG RATIO AVG 5Y
1.18
PEG RATIO AVG 10Y
1.10
PEG RATIO AVG 15Y
N/A
PEG RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+49.79%
CURRENT VS 3Y AVG
+60.00%
CURRENT VS 5Y AVG
+54.89%
CURRENT VS 10Y AVG
+65.00%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
MEDP Competitors' PEG Ratio
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | $13.14B | 1.82 | 1.22 | 1.14 | 1.18 |
| Solventum Corporation (SOLV)vs › | $13.06B | 0.04 | 0.04 | 117.61 | 78.52 |
| Align Technology, Inc. (ALGN)vs › | $13.04B | 51.77 | 51.77 | 26.79 | 17.89 |
| DaVita Inc. (DVA)vs › | $13.34B | 2.54 | 0.38 | 0.35 | 0.56 |
| The Cooper Companies, Inc. (COO)vs › | $12.85B | N/A | 1.65 | 0.83 | 0.60 |
| Revvity, Inc. (RVTY)vs › | $11.16B | 216.45 | 0.95 | 0.69 | 0.60 |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | N/A | 0.05 | 0.05 | 0.14 |
| Baxter International Inc. (BAX)vs › | $10.27B | N/A | 0.18 | 0.70 | 1.43 |
| Hologic, Inc. (HOLX)vs › | $16.97B | N/A | 0.30 | 0.22 | 1.95 |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $17.02B | N/A | 0.07 | 1.03 | 0.84 |
Growth-Adjusted Valuation
PEG Ratio
1.82
P/E Ratio
28.9
Medpace Holdings, Inc. PEG Ratio Formula & Definition
PEG Ratio = PE Ratio / Earnings Growth Rate
The PEG ratio adjusts the PE ratio for expected earnings growth. A PEG near 1 is often considered fairly valued relative to growth.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Medpace Holdings, Inc. PEG Ratio FAQ
- What is the PEG ratio for Medpace Holdings, Inc. (MEDP)?
- The PEG ratio for MEDP stock is 1.82.
- Is Medpace Holdings, Inc.'s PEG ratio high or low?
- Medpace Holdings, Inc.'s PEG ratio of 1.82 is 55% above its 5-year average of 1.18, near the high end of its 5-year range (0.57–1.82).
- What is the TTM average PEG ratio for Medpace Holdings, Inc. (MEDP)?
- The TTM average PEG ratio for MEDP stock is 1.22.
- What is the 3Y average PEG ratio for Medpace Holdings, Inc. (MEDP)?
- The 3Y average PEG ratio for MEDP stock is 1.14.
- What is the 5Y average PEG ratio for Medpace Holdings, Inc. (MEDP)?
- The 5Y average PEG ratio for MEDP stock is 1.18.
- What is the 10Y average PEG ratio for Medpace Holdings, Inc. (MEDP)?
- The 10Y average PEG ratio for MEDP stock is 1.10.
Medpace Holdings, Inc. PEG Ratio History
| DATE | PEG RATIO |
|---|---|
| 2025-12-31 | 1.82 |
| 2024-12-31 | 0.61 |
| 2023-12-31 | 1.55 |
| 2022-12-31 | 0.57 |
| 2021-12-31 | 1.76 |
| 2020-12-31 | 0.74 |
| 2019-12-31 | 0.83 |
| 2018-12-31 | 0.24 |
| 2017-12-31 | 0.22 |
| 2015-12-31 | 2.69 |
| 2014-12-31 | 0.38 |
Related Metrics
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle